The FDA has approved Alexion Pharmaceutical’s application providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. This update reflects Alexion’s fulfillment of post-marketing requirements, including the submission of confirmatory data from two additional prospective clinical trials, including one in pediatric patients with aHUS … more

— UPCOMING EVENTS —

5/12 5:00 pm – 6:30 pm in New Haven
BioScienceClubhouseCT presents ‘SystaMedic: A Novel Cause-Effect Analysis Platform for Predicting Probability of R&D Program Success’  … more

6/5 4:00 pm – 6:00 pm in New Haven
CURE annual meeting and BioHaven panel discussion: “Growing Connecticut’s Bioscience Community: Supporting Ideas, Creating Value” … more